[20200527]IN11347_新冠肺炎的治疗:羟基氯喹和氯喹 .pdf

上传人:任我行 文档编号:29362 上传时间:2022-06-24 发布时间:2020-05-27 格式:PDF 页数:4 大小:649.24KB
下载 相关 举报
[20200527]IN11347_新冠肺炎的治疗:羟基氯喹和氯喹 .pdf_第1页
第1页 / 共4页
[20200527]IN11347_新冠肺炎的治疗:羟基氯喹和氯喹 .pdf_第2页
第2页 / 共4页
[20200527]IN11347_新冠肺炎的治疗:羟基氯喹和氯喹 .pdf_第3页
第3页 / 共4页
[20200527]IN11347_新冠肺炎的治疗:羟基氯喹和氯喹 .pdf_第4页
第4页 / 共4页
亲,该文档总共4页,全部预览完了,如果喜欢就下载吧!
资源描述

1、CRS INSIGHT Prepared for Members and Committees of Congress INSIGHTINSIGHTi i Treatment of COVID-19: Hydroxychloroquine and Chloroquine Updated May 27, 2020 To date, the U.S. Food and Drug Administration (FDA) has not approved any therapeuticsdrugs or biologicsfor the treatment of COVID-19. However,

2、 FDA has authorized the emergency use of three drugs, including two drugs that have been approved by FDA for other uses: hydroxychloroquine sulfate (“hydroxychloroquine”) and chloroquine phosphate (“chloroquine”). The agency authorized the emergency use of both drugs on March 28, 2020, determining t

3、hat based on the totality of scientific evidence, “it is reasonable to believe that chloroquine and hydroxychloroquine may be effective in treating COVID-19,” and that when used in accord with the conditions of the emergency use authorization (EUA), the known and potential benefits outweigh the know

4、n and potential risks of these drugs. Some stakeholdersincluding several former FDA officialshave expressed concern regarding FDAs EUA, stating that current data regarding the safety and effectiveness of these drugs for treatment of COVID-19 are largely anecdotal and that expanding access may jeopar

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告